Nadim Tawil, Ali Bazarbachi, Hugues de Thé, Pierre Fenaux, Hervé Dombret, Mohamad Mohty, Nadine Darwiche, Kazem Zibara, Ala Salameh, Hiba El Hajj, Umut Sahin, Rita Hleihel, Olivier Legrand, Lionel Ades, Emmanuel Raffoux, Caroline Berthier, Zeina Dassouki
Journal: Blood 2015;125(22):3447-54
PMID: 25800051
Nucleophosmin-1 (NPM1) is the most frequently mutated gene in acute myeloid leukemia (AML). Addition of retinoic acid (RA) to chemotherapy was proposed to improve survival of some of these patients. Here, we found that RA or arsenic trioxide synergistically induce proteasomal degradation of mutant NPM1 in AML cell lines or primary samples, leading to differentiation and apoptosis. NPM1 mutation not only delocalizes NPM1 from the nucleolus, but it also disorganizes promyelocytic leukemia (PML) nuclear bodies. Combined RA/arsenic treatment significantly reduced bone marrow blasts in 3 patients and restored the subnuclear localization of both NPM1 and PML. These findings could explain the proposed benefit of adding RA to chemotherapy in NPM1 mutant AMLs, and warrant a broader clinical evaluation of regimen comprising a RA/arsenic combination.
© 2015 by The American Society of Hematology.
Full Text Sources:
Medical:
Other Literature Sources:
Full Text Sources:
© Copyright 2026, Nutrition Evidence
We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.